ClinicalTrials.gg
CompletedNCT03299244Updated Apr 30, 2021Results posted

Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT)

A Phase 3 interventional study of Etelcalcetide and Cinacalcet in Secondary Hyperparathyroidism and Chronic Kidney Disease, sponsored by Amgen. Completed at 90 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-30.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
637
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 16 studies testing etelcalcetide in Hyperparathyroidism, Secondary — 2 open to participants now, 2 under way, 2 of them phase 3. etelcalcetide · Hyperparathyroidism, Secondary.

Enrollment
4th of 16
637 · median 72
Started
2018
with 1 other
Phase 3
9 of 16
2 open now
Registered
14th of 16
by date
Lead sponsor
11 of 16
Amgen

Among the 16 studies testing etelcalcetide in Hyperparathyroidism, Secondary, this one is the 4th largest by enrollment, is one of 2 that started in 2018, is one of 9 in phase 3, and was the 14th registered.

Hyperparathyroidism, Secondary

188 studies on the registry are indexed under Hyperparathyroidism, Secondary; 15 are open to participants now.

Browse Hyperparathyroidism, Secondary studies →

Open to participants now

2 of the 16 studies testing etelcalcetide in Hyperparathyroidism, Secondary are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About etelcalcetide

etelcalcetide: first FDA approval 2017 (PARSABIV), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 10 Hyperparathyroidism, Secondary studies recruiting now, 5 (50%) set no upper age limit and 4 (40%) stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing etelcalcetide in Hyperparathyroidism, Secondary, or all of them as a file.
02

Study summary

The primary objective is to demonstrate that treatment with etelcalcetide (AMG 416) is not inferior to treatment with cinacalcet for lowering serum intact parathyroid hormone (PTH) levels by > 30% from baseline among participants with chronic kidney disease (CKD) and secondary hyperparathyroidism (SHPT) who require management with hemodialysis.

03

Conditions studied

  • Secondary Hyperparathyroidism
  • Chronic Kidney Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has provided prior to performing any study-related activities/procedures.
  • Male or female subjects ≥ 18 years of age or older at the time of signing informed consent.
  • Subject must be receiving maintenance hemodialysis 3 times weekly for at least 3 months, with adequate hemodialysis based on a delivered measure of dialysis adequacy (Kt/V) ≥ 1.2 or urea reduction ratio ≥ 65% within 4 weeks prior to screening laboratory assessments. The Kt/V formula used for a subject must be the formula used during routine care prior to screening.
  • Dialysate calcium concentration must be ≥ 2.5 mEq/L (1.25 mmol/L) and stable for at least 4 weeks prior to screening laboratory assessments, and must remain ≥ 2.5 mEq/L (1.25 mmol/L) for the duration of the study.
  • Subject must have SHPT as defined by one central laboratory screening predialysis serum PTH value > 500 pg/mL, within 2 weeks prior to randomization.
  • Subject currently receiving vitamin D sterols must have had no more than a maximum dose change of 50% within the 4 weeks prior to screening laboratory assessments, remain stable through randomization, and be expected to maintain stable doses for the duration of the study, except for adjustments allowed per protocol or for safety reasons.
  • Subject must have 1 screening predialysis serum cCa laboratory value ≥ 8.3 mg/dL measured within 2 weeks prior to randomization.
  • A subject receiving calcium supplements must have had no more than a maximum dose change of 50% within 2 weeks prior to screening laboratory assessments and remain stable through randomization.
  • A subject receiving phosphate binders must have had no more than a maximum dose change of 50% within the 2 weeks prior to screening laboratory assessments, remain stable through randomization, and be expected to maintain stable dose for the duration of the study, except for adjustments allowed per protocol or for safety reasons.

Exclusion criteria

Exclusion Criteria:

  • Currently receiving treatment in another device or drug study, or ≤ 30 days since ending treatment on another investigational device or drug study(s). Other investigational procedures while participating in this study are excluded.
  • Subject has received etelcalcetide in a prior clinical trial of etelcalcetide.
  • Subject has received cinacalcet during the 3 months prior to the first screening laboratory assessments.
  • Subject has known sensitivity to any of the products or components of either cinacalcet or etelcalcetide to be administered during dosing.
  • Subject has previously been randomized in this study.
  • Anticipated or scheduled parathyroidectomy during the study period.
  • Subject has received a parathyroidectomy within 6 months prior to dosing.
  • Anticipated or scheduled kidney transplant during the study period.
  • Subject has an unstable medical condition based on medical history, physical examination, and routine laboratory tests, or is otherwise unstable in the judgment of the Investigator.
  • within the last 5 years of screening (except non-melanoma skin cancers or cervical carcinoma in situ).
  • Grapefruit juice is prohibited.
  • Subject is pregnant or nursing, or planning to become pregnant or nurse during treatment or within 3 months after the last dose of etelcalcetide or 30 days after the last dose of cinacalcet
  • Female subject of who is unwilling to use an acceptable method of effective during treatment with investigational product (IP) through 3 months after the last dose of IP.
  • Subject has a history of symptomatic ventricular dysrhythmias or Torsades de Pointes.
  • Subject has a history of myocardial infarction, coronary angioplasty, or coronary arterial bypass grafting within the past 6 months prior to screening.
  • Subject has abnormalities on prestudy clinical examination or abnormalities on the most recent central laboratory tests during the screening period prior to randomization according to the Investigator including but not limited to the following:

    • serum albumin \< 3.0 g/dL
    • serum magnesium \< 1.5 mg/dL
    • serum transaminase ( [ALT] or serum glutamic pyruvic transaminase [SGPT], aspartate aminotransferase [AST] or serum glutamic oxaloacetic transaminase [SGOT]) > 3 times the (ULN) at screening.
  • Subject likely not available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the subject and Investigator's knowledge.
  • History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the Investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
637 participants (actual)

Study arms

  • Active comparator
    Cinacalcet

    Participants were randomized to receive oral cinacalcet once daily and placebo intravenous (IV) bolus injection at the end of each hemodialysis session three times per week (TIW) for 26 weeks. The starting dose of cinacalcet was 25 mg daily and the dose may have been titrated at weeks 5, 9, 13, and 17 to target predialysis serum parathyroid hormone (PTH) ≤ 300 pg/mL but no lower than 100 pg/mL while maintaining corrected calcium (cCa) ≥ 8.3 mg/dL.

    Drug: Cinacalcet

  • Experimental
    Etelcalcetide

    Participants were randomized to receive etelcalcetide administered by intravenous bolus injection at the end of each hemodialysis session TIW and daily oral doses of placebo tablets for 26 weeks. The starting dose of etelcalcetide was 5 mg, and the dose may have been titrated at weeks 5, 9, 13, and 17 to target predialysis serum PTH ≤ 300 pg/mL but no lower than 100 pg/mL while maintaining cCa ≥ 8.3 mg/dL.

    Drug: Etelcalcetide

Interventions

  • Administered intravenously three times per week.

    Also known as: AMG 416, Parsabiv®

  • Cinacalcet administered orally once a day.

    Also known as: Sensipar®, Mimpara®

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With > 30% Reduction From Baseline in Mean Predialysis Intact Parathyroid Hormone During the Efficacy Assessment Phase - Non-inferiority Analysis

    Predialysis intact parathyroid hormone (iPTH) levels were measured by a central laboratory.

    Time frame: Baseline and the efficacy assessment phase (EAP; defined as weeks 20 to 27, inclusive).

Secondary outcomes

  1. Percentage of Participants With > 50% Reduction From Baseline in Mean Predialysis iPTH During the Efficacy Assessment Phase

    Predialysis intact parathyroid hormone levels were measured by a central laboratory.

    Time frame: Baseline and the efficacy assessment phase (weeks 20 to 27, inclusive).

  2. Percentage of Participants With > 30% Reduction From Baseline in Mean Predialysis iPTH During the Efficacy Assessment Phase - Superiority Analysis

    Predialysis intact parathyroid hormone levels were measured by a central laboratory.

    Time frame: Baseline and the efficacy assessment phase (weeks 20 to 27, inclusive)

  3. Percent Change From Baseline in Mean Predialysis Corrected Calcium During the Efficacy Assessment Phase

    Predialysis corrected calcium was measured by a central laboratory.

    Time frame: Baseline and the efficacy assessment phase (weeks 20 - 27, inclusive)

  4. Percentage of Participants With Mean Predialysis Serum Phosphorus ≤ 4.5 mg/dL During the Efficacy Assessment Phase

    Predialysis serum phosphorus was measured by a central laboratory.

    Time frame: Efficacy assessment phase (weeks 20 - 27, inclusive)

Other outcomes

  1. Number of Participants With cCa < 8.3 mg/dL At Any Time During the Study

    Corrected calcium was measured by the central laboratory.

    Time frame: From first dose of study drug to end of study; up to 26 weeks + 30 days.

  2. Number of Participants With cCa < 8.0 mg/dL At Any Time During the Study

    Corrected calcium was measured by the central laboratory.

    Time frame: From first dose of study drug to end of study; up to 26 weeks + 30 days.

  3. Number of Participants With cCa < 7.5 mg/dL At Any Time During the Study

    Corrected calcium was measured by the central laboratory.

    Time frame: From first dose of study drug to end of study; up to 26 weeks + 30 days.

  4. Number of Participants With Treatment-emergent Symptomatic Hypocalcemia During the Study

    Common symptoms of hypocalcemia (diminished blood calcium) include paresthesias (fingertips, toes, or perioral), fatigue, muscle cramps, irritability or anxiety, tetany (eg, carpopedal spasm, laryngospasm), Chvostek's sign, seizures, and prolonged QT interval.

    Time frame: From first dose of study drug to 30 days after last dose; up to 26 weeks + 30 days.

  5. Number of Participants Who Developed Antibodies to Etelcalcetide

    Developing antibody incidence is defined as participants who were binding antibody positive post-baseline with a negative or no result at baseline.

    Time frame: From first dose of study drug to 30 days after last dose; up to 26 weeks + 30 days.

  6. Number of Participants With Treatment-emergent Adverse Events

    An adverse event is defined as any untoward medical occurrence in a clinical study participant, including worsening of a pre-existing medical condition. The event does not necessarily have a causal relationship with study treatment. The investigator assessed whether each adverse event was possibly related to study drug. A serious adverse event is defined as an adverse event that met at least 1 of the following serious criteria: * fatal * life threatening * required in-patient hospitalization or prolongation of existing hospitalization * resulted in persistent or significant disability/incapacity * congenital anomaly/birth defect * other medically important serious event

    Time frame: From first dose of study drug to 30 days after last dose; up to 26 weeks + 30 days.

07

Results

Posted Apr 30, 2021

Participant flow

This study was conducted at 84 centers including mainland China (43 centers), Hong Kong (2 centers), India (12 centers), South Korea (11 centers), Malaysia (4 centers), and Taiwan (12 centers). Participants were enrolled from 15 May 2018 to 12 September 2019.

Participant flow — Overall Study
MilestoneCinacalcetEtelcalcetide
Started317320
Received treatment315318
Completed270282
Not completed4738
Withdrew: Withdrawal by subject3429
Withdrew: Decision by sponsor45
Withdrew: Death94

Outcome measures

PrimaryPercentage of Participants With > 30% Reduction From Baseline in Mean Predialysis Intact Parathyroid Hormone During the Efficacy Assessment Phase - Non-inferiority Analysis

Predialysis intact parathyroid hormone (iPTH) levels were measured by a central laboratory.

Time frame:
Baseline and the efficacy assessment phase (EAP; defined as weeks 20 to 27, inclusive).
Reported as:
Number · percentage of participants
Percentage of Participants With > 30% Reduction From Baseline in Mean Predialysis Intact Parathyroid Hormone During the Efficacy Assessment Phase - Non-inferiority Analysis
percentage of participantsCinacalcetEtelcalcetide
Percentage of Participants With > 30% Reduction From Baseline in Mean Predialysis Intact Parathyroid Hormone During the Efficacy Assessment Phase - Non-inferiority Analysis66.271.9
Statistical analysis
  • Cinacalcet vs Etelcalcetide · Treatment difference: 4.52 · 95% CI -3.05 to 12.09Treatment difference (Etelcalcetide - Cinacalcet) stratified by screening iPTH level, screening cCa level, and country/region.
SecondaryPercentage of Participants With > 50% Reduction From Baseline in Mean Predialysis iPTH During the Efficacy Assessment Phase

Predialysis intact parathyroid hormone levels were measured by a central laboratory.

Time frame:
Baseline and the efficacy assessment phase (weeks 20 to 27, inclusive).
Reported as:
Number · percentage of participants
Percentage of Participants With > 50% Reduction From Baseline in Mean Predialysis iPTH During the Efficacy Assessment Phase
percentage of participantsCinacalcetEtelcalcetide
Percentage of Participants With > 50% Reduction From Baseline in Mean Predialysis iPTH During the Efficacy Assessment Phase41.659.1
Statistical analysis
  • Cinacalcet vs Etelcalcetide · Cochran-Mantel-Haenszel · p = <0.001 · Odds ratio (or): 2.02 · 95% CI 1.47 to 2.77Odds ratio (Etelcalcetide : Cinacalcet) stratified by screening iPTH level, screening cCa level, and country/region.
SecondaryPercentage of Participants With > 30% Reduction From Baseline in Mean Predialysis iPTH During the Efficacy Assessment Phase - Superiority Analysis

Predialysis intact parathyroid hormone levels were measured by a central laboratory.

Time frame:
Baseline and the efficacy assessment phase (weeks 20 to 27, inclusive)
Reported as:
Number · percentage of participants
Percentage of Participants With > 30% Reduction From Baseline in Mean Predialysis iPTH During the Efficacy Assessment Phase - Superiority Analysis
percentage of participantsCinacalcetEtelcalcetide
Percentage of Participants With > 30% Reduction From Baseline in Mean Predialysis iPTH During the Efficacy Assessment Phase - Superiority Analysis58.066.3
Statistical analysis
  • Cinacalcet vs Etelcalcetide · Cochran-Mantel-Haenszel · p = 0.033 · Odds ratio (or): 1.42 · 95% CI 1.03 to 1.96Odds ratio (Etelcalcetide : Cinacalcet) stratified by screening iPTH level, screening cCa level, and country/region.
SecondaryPercent Change From Baseline in Mean Predialysis Corrected Calcium During the Efficacy Assessment Phase

Predialysis corrected calcium was measured by a central laboratory.

Time frame:
Baseline and the efficacy assessment phase (weeks 20 - 27, inclusive)
Reported as:
Mean · percent change
Percent Change From Baseline in Mean Predialysis Corrected Calcium During the Efficacy Assessment Phase
percent changeCinacalcetEtelcalcetide
Percent Change From Baseline in Mean Predialysis Corrected Calcium During the Efficacy Assessment Phase-8.00 ± 0.50-10.69 ± 0.53
Statistical analysis
  • Cinacalcet vs Etelcalcetide · Mixed-effects Model Repeated Measures · p = <0.001 · Difference in least squares means: -2.82 · 95% CI -4.14 to -1.50Treatment difference (Etelcalcetide - Cinacalcet) stratified by screening iPTH level, screening cCa level, and country/region. Standard error of the mean is the standard error of the least squares means difference.
SecondaryPercentage of Participants With Mean Predialysis Serum Phosphorus ≤ 4.5 mg/dL During the Efficacy Assessment Phase

Predialysis serum phosphorus was measured by a central laboratory.

Time frame:
Efficacy assessment phase (weeks 20 - 27, inclusive)
Reported as:
Number · percentage of participants
Percentage of Participants With Mean Predialysis Serum Phosphorus ≤ 4.5 mg/dL During the Efficacy Assessment Phase
percentage of participantsCinacalcetEtelcalcetide
Percentage of Participants With Mean Predialysis Serum Phosphorus ≤ 4.5 mg/dL During the Efficacy Assessment Phase26.229.1
Statistical analysis
  • Cinacalcet vs Etelcalcetide · Cochran-Mantel-Haenszel · p = 0.41 · Odds ratio (or): 1.16 · 95% CI 0.82 to 1.65Odds ratio (Etelcalcetide : Cinacalcet) stratified by screening iPTH level, screening cCa level, and country/region.
Other pre-specifiedNumber of Participants With cCa < 8.3 mg/dL At Any Time During the Study

Corrected calcium was measured by the central laboratory.

Time frame:
From first dose of study drug to end of study; up to 26 weeks + 30 days.
Reported as:
Count of participants · Participants
Number of Participants With cCa < 8.3 mg/dL At Any Time During the Study
ParticipantsCinacalcetEtelcalcetide
Number of Participants With cCa < 8.3 mg/dL At Any Time During the Study245273
Other pre-specifiedNumber of Participants With cCa < 8.0 mg/dL At Any Time During the Study

Corrected calcium was measured by the central laboratory.

Time frame:
From first dose of study drug to end of study; up to 26 weeks + 30 days.
Reported as:
Count of participants · Participants
Number of Participants With cCa < 8.0 mg/dL At Any Time During the Study
ParticipantsCinacalcetEtelcalcetide
Number of Participants With cCa < 8.0 mg/dL At Any Time During the Study194241
Other pre-specifiedNumber of Participants With cCa < 7.5 mg/dL At Any Time During the Study

Corrected calcium was measured by the central laboratory.

Time frame:
From first dose of study drug to end of study; up to 26 weeks + 30 days.
Reported as:
Count of participants · Participants
Number of Participants With cCa < 7.5 mg/dL At Any Time During the Study
ParticipantsCinacalcetEtelcalcetide
Number of Participants With cCa < 7.5 mg/dL At Any Time During the Study61109
Other pre-specifiedNumber of Participants With Treatment-emergent Symptomatic Hypocalcemia During the Study

Common symptoms of hypocalcemia (diminished blood calcium) include paresthesias (fingertips, toes, or perioral), fatigue, muscle cramps, irritability or anxiety, tetany (eg, carpopedal spasm, laryngospasm), Chvostek's sign, seizures, and prolonged QT interval.

Time frame:
From first dose of study drug to 30 days after last dose; up to 26 weeks + 30 days.
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Symptomatic Hypocalcemia During the Study
ParticipantsCinacalcetEtelcalcetide
Number of Participants With Treatment-emergent Symptomatic Hypocalcemia During the Study1535
Other pre-specifiedNumber of Participants Who Developed Antibodies to Etelcalcetide

Developing antibody incidence is defined as participants who were binding antibody positive post-baseline with a negative or no result at baseline.

Time frame:
From first dose of study drug to 30 days after last dose; up to 26 weeks + 30 days.
Reported as:
Count of participants · Participants
Number of Participants Who Developed Antibodies to Etelcalcetide
ParticipantsEtelcalcetide
Number of Participants Who Developed Antibodies to Etelcalcetide18
Other pre-specifiedNumber of Participants With Treatment-emergent Adverse Events

An adverse event is defined as any untoward medical occurrence in a clinical study participant, including worsening of a pre-existing medical condition. The event does not necessarily have a causal relationship with study treatment. The investigator assessed whether each adverse event was possibly related to study drug. A serious adverse event is defined as an adverse event that met at least 1 of the following serious criteria: * fatal * life threatening * required in-patient hospitalization or prolongation of existing hospitalization * resulted in persistent or significant disability/incapacity * congenital anomaly/birth defect * other medically important serious event

Time frame:
From first dose of study drug to 30 days after last dose; up to 26 weeks + 30 days.
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events
ParticipantsCinacalcetEtelcalcetide
Any treatment-emergent adverse event (TEAE)303306
Serious adverse events6153
TEAEs leading to discontinuation of study drug159
Fatal adverse events94
Treatment-related TEAEs243250
Treatment-related serious adverse events44
Treatment-related TEAEs leading to discontinuation of study drug53
Treatment-related fatal adverse events11

Adverse events

Collected over From first dose of study drug to 30 days after last dose (up to 26 weeks + 30 days).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cinacalcet9/317 (2.8%)61/315 (19.4%)293/315 (93%)
Etelcalcetide4/320 (1.3%)53/318 (16.7%)294/318 (92.5%)
Most frequent serious events
Showing 10 of 106
Most frequent serious events
EventCinacalcetEtelcalcetide
PneumoniaInfections and infestations4/3157/318
Arteriovenous fistula occlusionInjury, poisoning and procedural complications3/3155/318
HypertensionVascular disorders1/3154/318
Acute myocardial infarctionCardiac disorders3/3150/318
End stage renal diseaseRenal and urinary disorders2/3153/318
Arteriosclerosis coronary arteryCardiac disorders2/3150/318
Cardiac failure acuteCardiac disorders2/3152/318
Coronary artery diseaseCardiac disorders2/3150/318
CataractEye disorders2/3150/318
PeritonitisInfections and infestations2/3151/318
Most frequent other events
Showing 10 of 25
Most frequent other events
EventCinacalcetEtelcalcetide
Blood calcium decreasedInvestigations218/315252/318
Muscle spasmsMusculoskeletal and connective tissue disorders37/31548/318
VomitingGastrointestinal disorders47/31530/318
NauseaGastrointestinal disorders45/31535/318
HypocalcaemiaMetabolism and nutrition disorders15/31535/318
HyperphosphataemiaMetabolism and nutrition disorders34/31526/318
Upper respiratory tract infectionInfections and infestations33/31534/318
HypotensionVascular disorders27/31534/318
NasopharyngitisInfections and infestations31/31528/318
CoughRespiratory, thoracic and mediastinal disorders29/31523/318

Baseline characteristics

The full analysis set includes all randomized participants.

Age, Continuous
Age, Continuous(years)CinacalcetEtelcalcetideTotal
Mean51.5 ± 12.952.2 ± 13.451.8 ± 13.1
Age, Customized
Age, Customized(Participants)CinacalcetEtelcalcetideTotal
18 - 64 years264262526
65 - 74 years454792
75 - 84 years8917
≥ 85 years022
Sex: Female, Male
Sex: Female, Male(Participants)CinacalcetEtelcalcetideTotal
Female138142280
Male179178357
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)CinacalcetEtelcalcetideTotal
Asian Indian191938
Chinese262270532
Other363167
Stratification Factor: Screening Intact Parathyroid Hormone (iPTH)
Stratification Factor: Screening Intact Parathyroid Hormone (iPTH)(Participants)CinacalcetEtelcalcetideTotal
< 900 pg/mL128131259
≥ 900 pg/mL189189378
Stratification Factor: Screening Corrected Calcium (cCa)
Stratification Factor: Screening Corrected Calcium (cCa)(Participants)CinacalcetEtelcalcetideTotal
< 9 mg/dL6264126
≥ 9 mg/dL255256511
Stratification Factor: Country/Region
Stratification Factor: Country/Region(Participants)CinacalcetEtelcalcetideTotal
China189191380
Non-China128129257
Intact Parathyroid Hormone Level
Intact Parathyroid Hormone Level(pg/mL)CinacalcetEtelcalcetideTotal
Mean1299.01 ± 830.991299.91 ± 853.821299.46 ± 841.87

3 further baseline measures are reported on the registry.

08

Study locations

90 sites
  • Research Site
    Beijing, Beijing 100034, China
  • Research Site
    Lanzhou, Gansu 730000, China
  • Research Site
    Guangzhou, Guangdong 510080, China
  • Research Site
    Guangzhou, Guangdong 510120, China
  • Research Site
    Guangzhou, Guangdong 510150, China
  • Research Site
    Guangzhou, Guangdong 510180, China
  • Research Site
    Guangzhou, Guangdong 510630, China
  • Research Site
    Shenzhen, Guangdong 518035, China
  • Research Site
    Zhanjiang, Guangdong 524001, China
  • Research Site
    Nanning, Guangxi 530021, China
  • Research Site
    Nanning, Guangxi 530022, China
  • Research Site
    Zhengzhou, Henan 450003, China
  • Research Site
    Zhengzhou, Henan 450052, China
  • Research Site
    Wuhan, Hubei 430030, China
  • Research Site
    Wuhan, Hubei 430034, China
  • Research Site
    Wuhan, Hubei 430060, China
  • Research Site
    Changsha, Hunan 410008, China
  • Research Site
    Changsha, Hunan 410011, China
  • Research Site
    Changzhou, Jiangsu 213003, China
  • Research Site
    Nanjing, Jiangsu 210009, China
  • Research Site
    Nanjing, Jiangsu 210029, China
  • Research Site
    Wuxi, Jiangsu 214023, China
  • Research Site
    Changchun, Jilin 130021, China
  • Research Site
    Changchun, Jilin 130041, China
  • Research Site
    Dalian, Liaoning 116001, China
  • Research Site
    Dalian, Liaoning 116011, China
  • Research Site
    Dalian, Liaoning 116027, China
  • Research Site
    Shenyang, Liaoning 110004, China
  • Research Site
    Shenyang, Liaoning 110022, China
  • Research Site
    Xian, Shaanxi 710004, China
  • Research Site
    Qingdao, Shandong 266005, China
  • Research Site
    Shanghai, Shanghai 200072, China
  • Research Site
    Shanghai, Shanghai 200090, China
  • Research Site
    Shanghai, Shanghai 200127, China
  • Research Site
    Shanghai, Shanghai 200240, China
  • Research Site
    Taiyuan, Shanxi 030001, China
  • Research Site
    Chengdu, Sichuan 610041, China
  • Research Site
    Chengdu, Sichuan 610072, China
  • Research Site
    Tianjin, Tianjin 300052, China
  • Research Site
    Tianjin, Tianjin 300121, China
  • Research Site
    Urumqi, Xinjiang 830054, China
  • Research Site
    Hangzhou, Zhejiang 310003, China
  • Research Site
    Hangzhou, Zhejiang 310009, China
  • Research Site
    Hong Kong, Hong Kong
  • Research Site
    Kowloon, Hong Kong
  • Research Site
    New Territories, Hong Kong
  • Research Site
    New Delhi, Delhi 110 017, India
  • Research Site
    New Delhi, Delhi 110 025, India
  • Research Site
    New Delhi, Delhi 110 060, India
  • Research Site
    New Delhi, Delhi 110 070, India
  • Research Site
    Ahmedabad, Gujarat 380 006, India
  • Research Site
    Nadiad, Gujarat 387 001, India
  • Research Site
    Belagavi, Karnataka 590010, India
  • Research Site
    Mysuru, Karnataka 570001, India
  • Research Site
    Kozhikode, Kerala 673 004, India
  • Research Site
    Kozhikode, Kerala 673 008, India
  • Research Site
    Chandigarh, Punjab 160 012, India
  • Research Site
    Chennai, Tamil Nadu 600 006, India
  • Research Site
    Lucknow, Uttar Pradesh 226 014, India
  • Research Site
    Dehradun, Uttaranchal 248 001, India
  • Research Site
    Wardha, 442 004, India
  • Research Site
    Busan, 602-715, Korea, Republic of
  • Research Site
    Busan, 602-739, Korea, Republic of
  • Research Site
    Daegu, 700-721, Korea, Republic of
  • Research Site
    Gumi-si, Gyeongsangbuk-do, 730-728, Korea, Republic of
  • Research Site
    Guri-si, Gyeonggi-do, 471-701, Korea, Republic of
  • Research Site
    Seoul, 130-872, Korea, Republic of
  • Research Site
    Seoul, 133-817, Korea, Republic of
  • Research Site
    Seoul, 134-727, Korea, Republic of
  • Research Site
    Seoul, 135-720, Korea, Republic of
  • Research Site
    Seoul, 150-950, Korea, Republic of
  • Research Site
    Seoul, 156-707, Korea, Republic of
  • Research Site
    Seoul, 156-755, Korea, Republic of
  • Research Site
    Ipoh, Perak 30450, Malaysia
  • Research Site
    George Town, Pinang 10990, Malaysia
  • Research Site
    Kuching, Sarawak 93586, Malaysia
  • Research Site
    Batu Caves, Selangor (incl. Putrajaya) 68100, Malaysia
  • Research Site
    Changhua, 50006, Taiwan
  • Research Site
    Kaohsiung, 83301, Taiwan
  • Research Site
    Keelung, 20401, Taiwan
  • Research Site
    New Taipei, 23561, Taiwan
  • Research Site
    Taichung, 40201, Taiwan
  • Research Site
    Taichung, 40705, Taiwan
  • Research Site
    Tainan, 70403, Taiwan
  • Research Site
    Tainan, 71004, Taiwan
  • Research Site
    Taipei, 10002, Taiwan
  • Research Site
    Taipei, 10449, Taiwan
  • Research Site
    Taipei, 11031, Taiwan
  • Research Site
    Taipei, 11101, Taiwan
  • Research Site
    Taoyuan, 33305, Taiwan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Apr 2020, 22 months.

Results were first posted in Apr 2021, 1 year after primary completion.

Of 21 phase 3 interventional studies under Hyperparathyroidism, Secondary, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 31. This study's 22 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2017
First posted
Oct 3, 2017
StartActual
May 15, 2018
Primary completionActual
Apr 8, 2020
CompletionActual
Apr 8, 2020
Results first posted
Apr 30, 2021
Last update
Apr 30, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03299244
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Oct 3, 2017
Start date
May 15, 2018
Primary completion
Apr 8, 2020
Completion
Apr 8, 2020
Results posted
Apr 30, 2021
Last update
Apr 30, 2021

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etelcalcetide

Start the discussion